The incidence of cardiovascular events after hospitalization due to CAP and their association with different inflammatory markers

BMC Pulmonary Medicine

Volumn 14, Issue 1, 2014, Pages

  Rajas, Olga ^a   Ortega Gómez, Mara ^a   Galván Román, José María ^a   Curbelo, José ^a   Fernández Jiménez, Guillermo ^a   Vega Piris, Lorena ^a   Rodríguez Salvanes, Francisco ^a   Arnalich, Belén ^b   Luquero Bueno, Sergio ^a   Díaz López, Ana ^c   de la Fuente, Hortensia ^c   Suárez, Carmen ^a   Ancochea, Julio ^a   Aspa, Javier ^a  

^a Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa   (Spain)

^b Refractive Surgeon at Clínica Baviera Madrid   (Spain)

^c HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

CAP late mortality; Cardiovascular events; Community acquired pneumonia (CAP); Inflammatory markers

Indexed keywords

BIOLOGICAL MARKER; COPEPTIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 6; PROADRENOMEDULLIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CD4+ T LYMPHOCYTE; COHORT ANALYSIS; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; DEATH; FOLLOW UP; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; PROGNOSIS; PROSPECTIVE STUDY; REGULATORY T LYMPHOCYTE; SAMPLE SIZE; SPAIN; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH17 CELL; UNIVERSITY HOSPITAL; ADULT; AGED; BLOOD; CARDIOVASCULAR DISEASES; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; IMMUNOLOGY; INCIDENCE; INFLAMMATION; MALE; MIDDLE AGED; PNEUMONIA, BACTERIAL;

ADULT; AGED; BIOMARKERS; CARDIOVASCULAR DISEASES; COHORT STUDIES; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HOSPITALIZATION; HUMANS; INCIDENCE; INFLAMMATION; MALE; MIDDLE AGED; PNEUMONIA, BACTERIAL; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 84924026830     PISSN: None     EISSN: 14712466     Source Type: Journal    
DOI: 10.1186/1471-2466-14-197     Document Type: Article

References (62)

1. World Health Organization: The top 10 causes of death. Geneva: World Health Organization; 2013. Available from http://www.who.int/mediacentre/factsheets/fs310/en/index.html
2. Welte T, Torres A, Nathwani D: Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax 2012, 67:71-79. 10.1136/thx.2009.129502
3. Wunderink RG, Waterer GW: Clinical practice. Community-acquired pneumonia. N Engl J Med 2014,370(6):543-551. 10.1056/NEJMcp1214869
4. Brancati FL, Chow JW, Wagener MM, Vacarello SJ, Yu VL: Is pneumonia really the old man's friend? Two-year prognosis after community-acquired pneumonia. Lancet 1993,342(8862):30-33. 10.1016/0140-6736(93)91887-R
5. Waterer GW, Kessler LA, Wunderink RG: Medium-term survival after hospitalization with community-acquired pneumonia. Am J Respir Crit Care Med 2004,169(8):910-914. 10.1164/rccm.200310-1448OC
6. Yende S, Angus DC, Ali IS, Somes G, Newman AB, Bauer D, Garcia M, Harris TB, Kritchevsky SB: Influence of comorbid conditions on long-term mortality after pneumonia in older people. J Am Geriatr Soc 2007,55(4):518-525. 10.1111/j.1532-5415.2007.01100.x
7. Bordon J, Wiemken T, Peyrani P, Paz ML, Gnoni M, Cabral P, Venero Mdel C, Ramirez J: Decrease in long-term survival for hospitalized patients with community-acquired pneumonia. Chest 2010,138(2):279-283. 10.1378/chest.09-2702
8. Johnstone J, Eurich DT, Majumdar SR, Jin Y, Marrie TJ: Long-term morbidity and mortality after hospitalization with community-acquired pneumonia: a population-based cohort study. Medicine (Baltimore) 2008,87(6):329-334. 10.1097/MD.0b013e318190f444
9. Adamuz J, Viasus D, Jimenez-Martinez E, Isla P, Garcia-Vidal C, Dorca J, Carratalà J: Incidence, timing and risk factors associated with 1-year mortality after hospitalization for community-acquired pneumonia. J Infect 2014, 68:534-541. 10.1016/j.jinf.2014.02.006
10. Kruger S, Frechen D: Cardiovascular complications and comorbidities in CAP. In European Respiratory monograph. Edited by: Chalmers JD, Pletz MW, Aliberti S. Sheffield: Europen Respiratory Society; 2014:256-265.
11. Corrales-Medina VF, Suh KN, Rose G, Chirinos JA, Doucette S, Cameron DW, Fergusson DA: Cardiac complications in patients with community-acquired pneumonia: a systematic review and meta-analysis of observational studies. PLoS Med 2011,8(6):e1001048. 10.1371/journal.pmed.1001048
12. Corrales-Medina VF, Musher DM, Wells GA, Chirinos JA, Chen L, Fine MJ: Cardiac complications in patients with community-acquired pneumonia: incidence, timing, risk factors, and association with short-term mortality. Circulation 2012,125(6):773-781. 10.1161/CIRCULATIONAHA.111.040766
13. Peyrani P, Ramirez J: What is the association of cardiovascular events with clinical failure in patients with community-acquired pneumonia? Infect Dis Clin North Am 2013,27(1):205-210. 10.1016/j.idc.2012.11.010
14. Perry TW, Pugh MJ, Waterer GW, Nakashima B, Orihuela CJ, Copeland LA, Restrepo MI, Anzueto A, Mortensen EM: Incidence of cardiovascular events after hospital admission for pneumonia. Am J Med 2011,124(3):244-251. 10.1016/j.amjmed.2010.11.014
15. Musher DM, Rueda AM, Kaka AS, Mapara SM: The association between pneumococcal pneumonia and acute cardiac events. Clin Infect Dis 2007,45(2):158-165. 10.1086/518849
16. Ramirez J, Aliberti S, Mirsaeidi M, Peyrani P, Filardo G, Amir A, Moffett B, Gordon J, Blasi F, Bordon J: Acute myocardial infarction in hospitalized patients with community-acquired pneumonia. Clin Infect Dis 2008,47(2):182-187. 10.1086/589246
17. Jasti H, Mortensen EM, Obrosky DS, Kapoor WN, Fine MJ: Causes and risk factors for rehospitalization of patients hospitalized with community-acquired pneumonia. Clin Infect Dis 2008,46(4):550-556. 10.1086/526526
18. Corrales-Medina VF, Serpa J, Rueda AM, Giordano TP, Bozkurt B, Madjid M, Tweardy D, Musher DM: Acute bacterial pneumonia is associated with the occurrence of acute coronary syndromes. Medicine (Baltimore) 2009,88(3):154-159. 10.1097/MD.0b013e3181a692f0
19. Milbrandt EB, Reade MC, Lee M, Shook SL, Angus DC, Kong L, Carter M, Yealy DM, Kellum JA: Prevalence and significance of coagulation abnormalities in community-acquired pneumonia. Mol Med 2009,15(11-12):438-445.
20. Madjid M, Miller CC, Zarubaev VV, Marinich IG, Kiselev OI, Lobzin YV, Filippov AE, Casscells 3rd SW: Influenza epidemics and acute respiratory disease activity are associated with a surge in autopsy-confirmed coronary heart disease death: results from 8 years of autopsies in 34,892 subjects. Eur Heart J 2007,28(10):1205-1210. 10.1093/eurheartj/ehm035
21. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P: Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med 2004,351(25):2611-2618. 10.1056/NEJMoa041747
22. Stoll G, Bendszus M: Inflammation and atherosclerosis: novel insights into plaque formation and destabilization. Stroke 2006,37(7):1923-1932. 10.1161/01.STR.0000226901.34927.10
23. Soto-Gomez N, Anzueto A, Waterer GW, Restrepo MI, Mortensen EM: Pneumonia: an arrhythmogenic disease? Am J Med 2013,126(1):43-48. 10.1016/j.amjmed.2012.08.005
24. Christ-Crain M, Morgenthaler NG, Stolz D, Muller C, Bingisser R, Harbarth S, Tamm M, Struck J, Bergmann A, Müller B: Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia[ISRCTN04176397]. Crit Care 2006,10(3):R96. 10.1186/cc4955
25. Kruger S, Ewig S, Giersdorf S, Hartmann O, Suttorp N, Welte T: Cardiovascular and inflammatory biomarkers to predict short- and long-term survival in community-acquired pneumonia: Results from the German Competence Network, CAPNETZ. Am J Respir Crit Care Med 2010,182(11):1426-1434. 10.1164/rccm.201003-0415OC
26. Kruger S, Welte T: Biomarkers in community-acquired pneumonia. Expert Rev Respir Med 2012,6(2):203-214. 10.1586/ers.12.6
27. Schuetz P, Litke A, Albrich WC, Mueller B: Blood biomarkers for personalized treatment and patient management decisions in community-acquired pneumonia. Curr Opin Infect Dis 2013,26(2):159-167.
28. Bello S, Lasierra AB, Minchole E, Fandos S, Ruiz MA, Vera E, de Pablo F, Ferrer M, Menendez R, Torres A: Prognostic power of proadrenomedullin in community-acquired peumonia is independent on etiology. Eur Respir J 2012,39(5):1144-1155. 10.1183/09031936.00080411
29. Martinez R, Menendez R, Reyes S, Polverino E, Cilloniz C, Martinez A, Esquinas C, Filella X, Ramírez P, Torres A: Factors associated with inflammatory cytokine patterns in community-acquired pneumonia. Eur Respir J 2011,37(2):393-399. 10.1183/09031936.00040710
30. Yende S, D'Angelo G, Kellum JA, Weissfeld L, Fine J, Welch RD, Kong L, Carter M, Angus DC: Inflammatory markers at hospital discharge predict subsequent mortality after pneumonia and sepsis. Am J Respir Crit Care Med 2008,177(11):1242-1247. 10.1164/rccm.200712-1777OC
31. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH: Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000,101(15):1767-1772. 10.1161/01.CIR.101.15.1767
32. Paats MS, Bergen IM, Hanselaar WE, van Zoelen EC, Verbrugh HA, Hoogsteden HC, van den Blink B, Hendriks RW, van der Eerden MM: T helper 17 cells are involved in the local and systemic inflammatory response in community-acquired pneumonia. Thorax 2014,68(5):468-474.
33. Kudva A, Scheller EV, Robinson KM, Crowe CR, Choi SM, Slight SR, Khader SA, Dubin PJ, Enelow RI, Kolls JK, Alcorn JF: Influenza A inhibits Th17-mediated host defense against bacterial pneumonia in mice. J Immunol 2011,186(3):1666-1674. 10.4049/jimmunol.1002194
34. Kolls JK, Khader SA: The role of Th17 cytokines in primary mucosal immunity. Cytokine Growth Factor Rev 2010,21(6):443-448. 10.1016/j.cytogfr.2010.11.002
35. Korn T, Oukka M, Kuchroo V, Bettelli E: Th17 cells: effector T cells with inflammatory properties. Semin Immunol 2007,19(6):362-371. 10.1016/j.smim.2007.10.007
36. Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA: Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol 2006, 24:99-146. 10.1146/annurev.immunol.24.021605.090737
37. Shevach EM: Biological functions of regulatory T cells. Adv Immunol 2011, 112:137-176.
38. Ley K, Laudanna C, Cybulsky MI, Nourshargh S: Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol 2007,7(9):678-689. 10.1038/nri2156
39. Demerath E, Towne B, Blangero J, Siervogel RM: The relationship of soluble ICAM-1, VCAM-1, P-selectin and E-selectin to cardiovascular disease risk factors in healthy men and women. Ann Hum Biol 2001,28(6):664-678. 10.1080/03014460110048530
40. Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987,40(5):373-383. 10.1016/0021-9681(87)90171-8
41. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, Ebrahim S, Faergeman O, Graham I, Mancia G, Cats VM, Orth-Gomér K, Perk J, Pyörälä K, Rodicio JL, Sans S, Sansoy V, Sechtem U, Silber S, Thomsen T, Wood D, European Society of Cardiology Committee for Practice Guidelines: European guidelines on cardiovascular disease prevention in clinical practice Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur J Cardio Prev Rev 2003,10(Suppl 1):S1-S78.
42. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, Lewis SA, Macfarlane JT: Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003,58(5):377-382. 10.1136/thorax.58.5.377
43. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley CM, Marrie TJ, Kapoor WN: A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997,336(4):243-250. 10.1056/NEJM199701233360402
44. Corrales-Medina VF, Taljaard M, Fine MJ, Dwivedi G, Perry JJ, Musher DM, Chirinos JA: Risk stratification for cardiac complications in patients hospitalized for community-acquired pneumonia. Mayo Clin Proc 2014,89(1):60-68. 10.1016/j.mayocp.2013.09.015
45. Viasus D, Garcia-Vidal C, Manresa F, Dorca J, Gudiol F, Carratala J: Risk stratification and prognosis of acute cardiac events in hospitalized adults with community-acquired pneumonia. J Infect 2013,66(1):27-33. 10.1016/j.jinf.2012.09.003
46. Torres A, Ramirez P, Montull B, Menendez R: Biomarkers and community-acquired pneumonia: tailoring management with biological data. Semin Respir Crit Care Med 2012,33(3):266-271.
47. Kruger S, Welte T, Ewig S: Another view on the prediction of outcomes in patients with community-acquired pneumonia. Eur Respir J 2011,38(4):991-992. author reply 992-3 10.1183/09031936.00039411
48. Ewig S, Torres A: Community-acquired pneumonia as an emergency: time for an aggressive intervention to lower mortality. Eur Respir J 2011,38(2):253-260. 10.1183/09031936.00199810
49. Fernandez-Botran R, Uriarte SM, Arnold FW, Rodriguez-Hernandez L, Rane MJ, Peyrani P, Wiemken T, Kelley R, Uppatla S, Cavallazzi R, Blasi F, Morlacchi L, Aliberti S, Jonsson C, Ramirez JA, Bordon J: Contrasting Inflammatory Responses in Severe and Non-severe Community-acquired Pneumonia. Inflammation 2014, 2014:2014.
50. Paats MS, Bergen IM, Hanselaar WE, van Groeninx Zoelen EC, Hoogsteden HC, Hendriks RW, van der Eerden MM: Local and systemic cytokine profiles in nonsevere and severe community-acquired pneumonia. Eur Respir J 2013,41(6):1378-1385. 10.1183/09031936.00060112
51. Ramirez P, Ferrer M, Marti V, Reyes S, Martinez R, Menendez R, Ewig S, Torres A: Inflammatory biomarkers and prediction for intensive care unit admission in severe community-acquired pneumonia. Crit Care Med 2011,39(10):2211-2217. 10.1097/CCM.0b013e3182257445
52. Craig A, Mai J, Cai S, Jeyaseelan S: Neutrophil recruitment to the lungs during bacterial pneumonia. Infect Immun 2009,77(2):568-575. 10.1128/IAI.00832-08
53. Bordon J, Aliberti S, Fernandez-Botran R, Uriarte SM, Rane MJ, Duvvuri P, Peyrani P, Morlacchi LC, Blasi F, Ramirez JA: Understanding the roles of cytokines and neutrophil activity and neutrophil apoptosis in the protective versus deleterious inflammatory response in pneumonia. Int J Infect Dis 2013,17(2):e76-e83. 10.1016/j.ijid.2012.06.006
54. Menendez R, Sahuquillo-Arce JM, Reyes S, Martinez R, Polverino E, Cilloniz C, Cilloniz C, Cordoba JG, Montull B, Torres A: Cytokine activation patterns and biomarkers are influenced by microorganisms in community-acquired pneumonia. Chest 2012,141(6):1537-1545. 10.1378/chest.11-1446
55. Calbo E, Garau J: Of mice and men: innate immunity in pneumococcal pneumonia. Int J Antimicrob Agents 2010,35(2):107-113. 10.1016/j.ijantimicag.2009.10.002
56. Kruger S, Ewig S, Kunde J, Hartmann O, Marre R, Suttorp N, Welte T: Assessment of inflammatory markers in patients with community-acquired pneumonia-influence of antimicrobial pre-treatment: results from the German competence network CAPNETZ. Clin Chim Acta 2010,411(23-24):1929-1934.
57. Kellum JA, Kong L, Fink MP, Weissfeld LA, Yealy DM, Pinsky MR, Fine J, Krichevsky A, Delude RL, Angus DC: Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Arch Intern Med 2007,167(15):1655-1663. 10.1001/archinte.167.15.1655
58. Remick DG, Bolgos G, Copeland S, Siddiqui J: Role of interleukin-6 in mortality from and physiologic response to sepsis. Infect Immun 2005,73(5):2751-2757. 10.1128/IAI.73.5.2751-2757.2005
59. Yende S, Tuomanen EI, Wunderink R, Kanaya A, Newman AB, Harris T, de Rekeneire N, Kritchevsky SB: Preinfection systemic inflammatory markers and risk of hospitalization due to pneumonia. Am J Respir Crit Care Med 2005,172(11):1440-1446. 10.1164/rccm.200506-888OC
60. El Solh A, Pineda L, Bouquin P, Mankowski C: Determinants of short and long term functional recovery after hospitalization for community-acquired pneumonia in the elderly: role of inflammatory markers. BMC Geriatr 2006, 6:12. 10.1186/1471-2318-6-12
61. Mortensen EM, Coley CM, Singer DE, Marrie TJ, Obrosky DS, Kapoor WN, Fine MJ: Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team cohort study. Arch Intern Med 2002,162(9):1059-1064. 10.1001/archinte.162.9.1059
62. Riley RD, Hayden JA, Steyerberg EW, Moons KG, Abrams K, Kyzas PA, Malats N, Briggs A, Schroter S, Altman DG, Hemingway H: Prognosis Research Strategy (PROGRESS) 2: prognostic factor research. PLoS Med 2013,10(2):e1001380. 10.1371/journal.pmed.1001380